A shuttered Milanese manufacturing site with a storied history is getting a new lease on life, thanks to a nearly half-a-billion-dollar investment from Italian drugmaker Chiesi. As part of an ongoing ...
Agreement builds on existing Chiesi-Bespak collaboration, reinforcing a trusted relationship as Chiesi works to evolve a portfolio of extrafine formulation Carbon Minimal Inhalers 1, ensuring patients ...
Findings showed BDP/FF/G improved predose FEV1 and reduced the rate of moderate to severe exacerbations compared with BDP/FF. The Food and Drug Administration (FDA) has accepted for review the New ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Chiesi USA's asthma inhaler ...
GRAND RAPIDS, Mich. (WOOD) — Many people manage their asthma with an inhaler — but they may not be using it correctly. Studies show that nearly 90% of patients with an inhaler make at least one ...
Chiesi Group (Chiesi), the international research focused biopharmaceutical company and a certified B Corp, and Bespak, the specialist inhalation CDMO focused on pulmonary and nasal drug delivery, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results